久吾高科(300631) - 2021 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2021 was ¥539,773,421.30, representing a year-over-year increase of 1.60% compared to ¥531,269,507.27 in 2020[21]. - The net profit attributable to shareholders for 2021 was ¥70,124,270.08, a decrease of 15.24% from ¥82,732,790.35 in 2020[21]. - The net profit after deducting non-recurring gains and losses was ¥26,224,621.18, down 58.52% from ¥63,217,051.08 in 2020[21]. - The net cash flow from operating activities increased significantly by 275.50% to ¥26,452,979.25 from ¥7,044,644.73 in 2020[21]. - The total assets at the end of 2021 were ¥1,522,824,726.68, an increase of 8.22% from ¥1,407,181,784.90 at the end of 2020[21]. - The net assets attributable to shareholders increased by 31.60% to ¥1,079,897,413.46 from ¥820,617,690.61 at the end of 2020[21]. - The company reported a basic earnings per share of ¥0.6305, down 20.50% from ¥0.7931 in 2020[21]. - The overall gross margin declined due to rising raw material and labor costs, as well as increased market competition[48]. - The company achieved operating revenue of 540 million yuan in 2021, a year-on-year increase of 1.6%[48]. - Net profit attributable to the parent company was 70.12 million yuan, a decrease of 15.24% compared to the previous year[48]. Research and Development - The company has established a complete R&D system for membrane materials and separation technology, promoting continuous technological innovation[38]. - The company has invested CNY 42.9352 million in R&D, accounting for 7.95% of its revenue, ensuring continuous improvement in technology and product development capabilities[44]. - Research and development expenses increased year-on-year, contributing to the decline in net profit[49]. - The company has increased its R&D personnel by 17.74%, with a total of 73 R&D staff, which now constitutes 18.91% of the workforce[65]. - The company plans to develop and optimize organic membrane materials, enhancing its position in the separation membrane industry[65]. - The company's R&D investment in 2021 amounted to ¥42,935,151.10, representing 7.95% of total revenue, an increase from 5.44% in 2020[66]. Market Position and Strategy - The company is focused on the research and application of membrane materials and membrane separation technology, which are considered key strategic materials in the new materials industry[32]. - The company has established a strong position in the domestic ceramic membrane technology sector and has developed comprehensive membrane integration technology solutions[33]. - The total production value of China's separation membrane-related industry is expected to exceed ¥360 billion in 2022, indicating significant market growth potential[33]. - The company actively participates in the lithium battery supply chain, focusing on the core processes and materials for lithium extraction from salt lake brine[39]. - The company plans to strengthen strategic cooperation and market expansion, particularly in high-growth sectors such as lithium extraction from salt lakes and clean production of iron phosphate[92]. - The company aims to enhance project delivery efficiency and operational management capabilities while ensuring quality and cost reduction[93]. Corporate Governance - The company maintains a strong governance structure, adhering to relevant laws and regulations, and ensuring the protection of shareholder interests[101]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[102]. - The company has established independent personnel management and compensation systems, ensuring that key management personnel are not involved with the controlling shareholder[106]. - The company has a dedicated audit risk control department that reports directly to the audit committee, enhancing internal audit effectiveness[107]. - The company has established a performance evaluation system linking the income of senior management to their work performance, ensuring accountability and motivation[103]. Environmental and Social Responsibility - The company has established an environmental management system in accordance with GB/T 24001-2016/ISO 14001:2015 standards to minimize negative environmental impacts[169]. - The company has not faced any administrative penalties due to environmental issues during the reporting period[170]. - The company actively engages in social welfare by providing scholarships to underprivileged university students, demonstrating its commitment to social responsibility[173]. - The company has implemented measures such as updating old equipment and promoting paperless operations to enhance environmental sustainability[173]. Shareholder Relations and Dividends - The company plans to distribute a cash dividend of 1.50 CNY per 10 shares, totaling 18,396,303.60 CNY for the year 2021[146]. - The cash dividend distribution represents 100% of the total profit distribution amount[146]. - The company has a clear profit distribution and cash dividend policy that complies with regulatory requirements[170]. - The company has implemented an employee stock incentive plan, with the first grant of restricted stock occurring on November 6, 2018, totaling 293,000 shares[153]. Risks and Challenges - The ongoing COVID-19 pandemic poses uncertainties that could adversely affect the company's overall performance, prompting the company to closely monitor developments and implement preventive measures[95]. - The company faces competition risks in the membrane separation industry, necessitating continuous R&D investment and market expansion efforts[93]. - The company anticipates an increase in accounts receivable due to business growth, with a focus on improving collection management and enhancing the proportion of quality customers to mitigate risks[94].